Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates ...Middle East

Company recently announced definitive agreement to be acquired by AstraZeneca FPI-2265 Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) expected to begin in Q2 2024 Interim data from TATCIST study of FPI-2265 to be presented at the...

Hence then, the article about fusion pharmaceuticals reports fourth quarter and full year 2023 financial results and announces clinical program updates was published today ( Wednesday 20/03/2024 - 11:08 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates )

Also on site :

• Bagel Bites Debuts New Snack Style That Has Fans 'Salivating'
• CBS Isn’t Suppressing Stephen Colbert’s ‘Only in Monroe’ Public Access Show, It’s On His New YouTube Channel
• From Pakistan to Shanghai: A CAR-T Journey Fighting Relapsed Lymphoma